In this analysis, we extrapolated VE data from PATRICIA to Africa, thereby implicitly assuming that VE would not differ between Africa

and the regions included in the trial. Recent study results in African girls and women showed that immune responses were similar to those observed in European populations thus strengthening our assumption [26]. Our study has limitations. Although, we have used country-specific data from WHO databases to ensure consistency by the use of the same data source, these estimates may differ from local epidemiological data of the countries. Second, our estimates are derived at vaccine steady-state, which in a real-life setting will need many years to be achieved. Consequently, the full potential of reduction in CC cases and deaths estimated here will need time to be realised. However, the estimated potential reductions in high-grade CIN could be observed earlier. For example, in Australia, where a large catch up for the find more HPV vaccination programme was put in place, a significant reduction in the incidence of high-grade lesions was observed within three years of introduction of the HPV vaccination programme

[27]. We have also assumed that the cross-protective effect of vaccination will have the same duration as vaccine-type HPV. Recent data from an independently conducted clinical trial reported persistence of cross-neutralizing antibody titres 3 years after vaccination, suggesting that cross-reactive antibody responses are likely to persist long-term [29]. learn more This was further corroborated by data from the follow-up of the phase II trial of the AS04-adjuvanted HPV-16/18 vaccine have demonstrated cross-reactive immune response that is sustained up to at least 7 years post vaccination. found This strengthens our assumption that the cross-protective effect demonstrated in the PATRICIA trial may be of long duration [28].

The estimated benefits of vaccination could however be less than projected, should the cross-protection be demonstrated to wane over time. Lastly, our estimates did not take account herd immunity effects, and thus we may have underestimated the potential effect of HPV vaccination. Our evaluation estimates that vaccination of young girls naïve to HPV with the AS04-adjuvanted HPV-16/18 vaccine could result in reductions in the number of CC cases and deaths in countries worldwide resulting in lives saved and CC-related cost-offsets. A proportion of the estimated potential reduction relates to protection against non-HPV-16/18 related HPV types. Additionally, prevention of precancerous lesions could reduce the morbidity associated with these lesions and result in further cost-savings. The authors are grateful to Carole Nadin (Fleetwith Ltd. c/o GlaxoSmithKline Vaccines) for medical writing assistance and Maud Boyer and Sarah Fico (both Business and Decision Life Sciences c/o GlaxoSmithKline Vaccines) for editorial assistance and publication co-ordination.